Laverman GD - Search Results

1

Dual renin-angiotensin system blockade at optimal doses for proteinuria.

Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Laverman GD, et al. Kidney Int. 2002 Sep;62(3):1020-5. doi: 10.1046/j.1523-1755.2002.00536.x. Kidney Int. 2002. PMID: 12164886 Free article. Clinical Trial.

2

A Digital Lifestyle Coach (E-Supporter 1.0) to Support People With Type 2 Diabetes: Participatory Development Study.

Hietbrink EAG, Middelweerd A, van Empelen P, Preuhs K, Konijnendijk AAJ, Oude Nijeweme-d'Hollosy W, Schrijver LK, Laverman GD, Vollenbroek-Hutten MMR. Hietbrink EAG, et al. Among authors: laverman gd. JMIR Hum Factors. 2023 Jan 12;10:e40017. doi: 10.2196/40017. JMIR Hum Factors. 2023. PMID: 36633898 Free PMC article.

3

Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.

Sen T, Curovic VR, Jongs N, Laverman GD, Kooy A, Persson F, Rossing P, Heerspink HJL. Sen T, et al. Among authors: laverman gd. Diabetes Obes Metab. 2023 Aug;25(8):2413-2418. doi: 10.1111/dom.15109. Epub 2023 May 11. Diabetes Obes Metab. 2023. PMID: 37166080 No abstract available.

4

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.

Laursen JC, Rotbain Curovic V, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Frimodt-Møller M, Laverman GD, Kooy A, Persson F, Heerspink HJL, Hansen CS, Rossing P. Laursen JC, et al. Among authors: laverman gd. Diabetes Obes Metab. 2023 Oct;25(10):3064-3067. doi: 10.1111/dom.15180. Epub 2023 Jun 29. Diabetes Obes Metab. 2023. PMID: 37385968 Clinical Trial. No abstract available.

5

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D. Laverman GD, et al. Am J Kidney Dis. 2001 Dec;38(6):1381-4. doi: 10.1053/ajkd.2001.29262. Am J Kidney Dis. 2001. PMID: 11728979 Clinical Trial.

6

Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.

Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Laverman GD, et al. Kidney Int. 2003 Jan;63(1):64-71. doi: 10.1046/j.1523-1755.2003.00708.x. Kidney Int. 2003. PMID: 12472769 Free article.

7

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?

Laverman GD, de Zeeuw D, Navis G. Laverman GD, et al. J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):205-13. doi: 10.3317/jraas.2002.042. J Renin Angiotensin Aldosterone Syst. 2002. PMID: 12584664 Free article. Review.

8

The COOPERATE trial.

Vogt L, Laverman GD, de Zeeuw D, Navis G. Vogt L, et al. Among authors: laverman gd. Lancet. 2003 Mar 22;361(9362):1055-6. doi: 10.1016/S0140-6736(03)12803-6. Lancet. 2003. PMID: 12660079 No abstract available.

9

Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.

Bos H, Laverman GD, Henning RH, Tiebosch AT, de Jong PE, de Zeeuw D, Navis G. Bos H, et al. Among authors: laverman gd. J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):106-12. doi: 10.3317/jraas.2003.010. J Renin Angiotensin Aldosterone Syst. 2003. PMID: 12806593 Free article.

10

Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage.

Kramer AB, Laverman GD, van Goor H, Navis G. Kramer AB, et al. Among authors: laverman gd. J Pathol. 2003 Sep;201(1):160-7. doi: 10.1002/path.1405. J Pathol. 2003. PMID: 12950029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters